Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer.
Karen E SkinnerAmin HaideraliMin HuangLee S SchwartzbergPublished in: Future oncology (London, England) (2020)
Aim: This study examined treatment patterns and effectiveness outcomes of patients with metastatic triple-negative breast cancer (mTNBC) from US community oncology centers. Materials & methods: Eligible patients were females, aged ≥18 years, diagnosed with mTNBC between 1 January 2010 and 31 January 2016. Kaplan-Meier and Cox regression methods were used. Results: Sample comprised 608 patients with average age of 57.5 years and 505/608 patients (83.1%) received systemic treatment. Overall survival (OS) from first-line treatment found that African-American patients had shorter OS than White (9.3 vs 13.7 months; hazard ratio: 1.35; p = 0.006). Conclusion: More than 15% of women with mTNBC were not treated, indicating a high unmet need. Overall prognosis remains poor, which highlights the opportunity for newer therapies to improve progression-free survival and OS.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- healthcare
- systematic review
- small cell lung cancer
- squamous cell carcinoma
- free survival
- metabolic syndrome
- mental health
- adipose tissue
- palliative care
- type diabetes
- skeletal muscle
- patient reported outcomes
- smoking cessation